Treatment of recalcitrant generalized granuloma annulare with adalimumab.

Abstract

Granuloma annulare is a benign, usually self-limited, dermatosis of unknown cause. Generalized lesions occur in approximately 15 percent of patients with GA and may cause mild to severe cosmetic disfigurement. The treatment of generalized granuloma annulare can be challenging. We report the case of a 36-year-old male patient with a generalized granuloma annulare who had failed topical and systemic glucocorticoids, systemic retinoids, dapsone, minocycline, PUVA therapy, and hydroxicloroquine and was successfully treated with adalimumab, an anti-TNF-α monoclonal antibody. Adalimumab may be an additional option in the treatment of recalcitrant forms of granuloma annulare.

• Authors: Tiago Torres, Teresa Pinto Almeida, Rosario Alves, Madalena Sanches, Manuela Selores
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 10 Issue 12 Pg. 1466-8 (Dec 2011) ISSN: 1545-9616 [Print] United States
• PMID: 22134573 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal, Humanized
• Adalimumab

Topics

• Adalimumab
• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Granuloma Annulare (drug therapy, pathology)
• Humans
• Male
• Treatment Outcome